COREssence
FDA approved Osimertinib (Tagrisso) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have...
PDL-1 expression has already shown us favorable prognosis in treatment of many solid cancers. As per latest advancements, PDL-1...
“So much to read, so little time!”
Does that sound familiar to you?
Being abreast of the latest developments – in science and in clinical practice can be of tremendous help – if only you had enough time to read.
We would like to help.
COREssence brings you a collection of scientific developments in in form of small, bite-size summaries.
[newsletter_form]
[newsletter_field name="email" placeholder="email@address.com"]
[/newsletter_form]
